Microscopic Polyangiitis Clinical Trials

4 recruiting

Microscopic Polyangiitis Trials at a Glance

8 actively recruiting trials for microscopic polyangiitis are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 1 trial, with the heaviest enrollment activity in Hamilton, Toronto, and Salt Lake City. Lead sponsors running microscopic polyangiitis studies include University of Pennsylvania, Essen Biotech, and Kissei Pharmaceutical Co., Ltd..

Browse microscopic polyangiitis trials by phase

Treatments under study

About Microscopic Polyangiitis Clinical Trials

Looking for clinical trials for Microscopic Polyangiitis? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Microscopic Polyangiitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Microscopic Polyangiitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Phase 3

Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)

Granulomatosis With PolyangiitisMicroscopic Polyangiitis (MPA)
Ottawa Hospital Research Institute36 enrolled2 locationsNCT06983821
Recruiting

VCRC Tissue Repository

Microscopic PolyangiitisGiant Cell ArteritisTakayasu Arteritis+8 more
University of Pennsylvania1,000 enrolled8 locationsNCT02967068
Recruiting

One-Time DNA Study for Vasculitis

Microscopic PolyangiitisGiant Cell ArteritisTakayasu's Arteritis+3 more
University of Pennsylvania1,000 enrolled14 locationsNCT01241305
Recruiting

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

VasculitisIgA VasculitisMicroscopic Polyangiitis (MPA)+7 more
Peter Merkel50 enrolled10 locationsNCT03004326
Recruiting

Vasculitis Pregnancy Registry

Behcet's DiseaseVasculitisCNS Vasculitis+12 more
University of Pennsylvania100 enrolled1 locationNCT02593565
Recruiting

Special Drug Use-results Survey for Long-term Use(Avacopan)

Microscopic Polyangiitis (MPA)Granulomatosis With Polyangiitis (GPA)
Kissei Pharmaceutical Co., Ltd.250 enrolled1 locationNCT06758271
Recruiting
Phase 1Phase 2

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

Systemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSjogren's Syndrome+6 more
Essen Biotech75 enrolled1 locationNCT06350110